Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763811 | 1.00 | PDPK1 (0.43) | PDPK1MTORL3MBTL1TP53MDM2 | |
| SCHEMBL9706806 | 0.83 | PDPK1 (0.52) | PDPK1MTORRECQLTSHRCETP | |
| SCHEMBL9706801 | 0.83 | PDPK1 (0.52) | PDPK1MTORRECQLTSHRCETP | |
| SCHEMBL1764547 | 0.82 | PDPK1 (0.42) | PDPK1MTORL3MBTL1TP53MDM2 | |
| SCHEMBL4913891 | 0.82 | PDPK1 (0.42) | PDPK1MTORL3MBTL1TP53MDM2 | |
| SCHEMBL15504384 | 0.80 | L3MBTL1 (0.53) | PDPK1MTORL3MBTL1TP53MDM2 | |
| SCHEMBL23563202 | 0.79 | ALDH1A1 (0.39) | PDPK1MTORLMNAKMT2AALDH1A1 | |
| SCHEMBL9300189 | 0.79 | ALDH1A1 (0.39) | PDPK1MTORLMNAKMT2AALDH1A1 | |
| SCHEMBL14268497 | 0.79 | ALDH1A1 (0.39) | PDPK1MTORLMNAKMT2AALDH1A1 | |
| SCHEMBL9706851 | 0.79 | ALDH1A1 (0.39) | PDPK1MTORLMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618269-B2 | Glycorandomization and production of novel novobiocin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | PDPK1 2809/4885MTOR 3668/4885L3MBTL1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.